A study of the combination of oxaliplatin, capecitabine, and trastuzumab and chemo-radiotherapy in the adjuvant setting in operated patients with HER2+gastric or gastroesophageal junction cancer (TOXAG study).

Abali, Huseyin; Yalcin, Suayib; Onal, Cem; Dane, Faysal; Oksuzoglu, Berna; Ozdemir, Nuriye; Mertsoylu, Huseyin; Artac, Mehmet; Camci, Celaletdin; Karabulut, Bulent; Basal, Fatma Bugdayci; Budakoglu, Burcin; Sendur, Mehmet Ali Nahit; Goktas, Burce; Ozdener, Fatih; Baygul, Arzu

doi:10.1200/JCO.2018.36.4\_suppl.26

A study of the combination of oxaliplatin, capecitabine, and trastuzumab and chemo-radiotherapy in the adjuvant setting in operated patients with HER2+gastric or gastroesophageal junction cancer (TOXAG study).

Date

2018

Authors

dc.identifier.doi

10.1200/JCO.2018.36.4\_suppl.26

dc.identifier.other

WOS:000436174100026

Publisher

LIPPINCOTT WILLIAMS \& WILKINS

DOI

10.1200/JCO.2018.36.4\_suppl.26

Abstract

Gastrointestinal Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), San Francisco, CA, JAN 18-20, 2018

URI

https://openaccess.acibadem.edu.tr/handle/11443/8317

Collections

WOS

Full item page

A study of the combination of oxaliplatin, capecitabine, and trastuzumab and chemo-radiotherapy in the adjuvant setting in operated patients with HER2+gastric or gastroesophageal junction cancer (TOXAG study).

Date

Authors

Journal Title

Journal ISSN

Volume Title

dc.identifier.issn

dc.identifier.doi

dc.identifier.other

dc.description.volume

dc.description.issue

Publisher

DOI

Abstract

Description

Keywords

Citation

URI

Collections

Endorsement

Review

Supplemented By

Referenced By